HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Feb. 06, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:​HCM; HKEX:​13) today announces that data from FRUTIGA, HUTCHMED's Phase III trial of fruquintinib in combination with paclitaxel for the treatment of second-line advanced gastric cancer in China, were presented at the American Society of Clinical Oncology ("ASCO") Plenary Series Session on February 6, 2024. The full presentation can be found here. Fruquintinib is a selec ...

Inmagene exercised its option under the previously announced collaboration agreement to obtain an exclusive, royalty-bearing license for IMG-007, an anti-OX40 monoclonal antibody (mAb) and IMG-004, a Bruton Tyrosine Kinase (BTK) inhibitor Inmagene retains rights to develop and commercialize both assets worldwide SAN DIEGO, Feb. 2, 2024 /PRNewswire/ -- Inmagene Biopharmaceuticals ("Inmagene" or the "Company"), a clinical stage biotechnology company developing innovative and differentiated therapies for imm ...

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Feb. 02, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:​HCM; HKEX:​13) today announced that, Inmagene Biopharmaceuticals ("Inmagene") has exercised options to license two drug candidates discovered by HUTCHMED, IMG-007 and IMG-004 (the "Options") pursuant to the terms of the strategic partnership announced on January 11, 2021. Following the exercise of the Options and subject to receipt by HUTCHMED of ordinary shares represen ...

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Feb. 01, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13) will be announcing its final results for the year ended December 31, 2023 on Wednesday, February 28, 2024 at 6:30 am Eastern Standard Time (EST) / 11:30 am Greenwich Mean Time (GMT) / 7:30 pm Hong Kong Time (HKT). Analysts and investors are invited to join a conference call and audio webcast presentation with Q&A, conducted by HUTCHMED management. The Engli ...

Core Viewpoint - HUTCHMED (China) Limited is set to announce its final results for the year ended December 31, 2023, on February 28, 2024, indicating a significant upcoming event for investors and analysts [1]. Group 1: Financial Results Announcement - The final results announcement will occur at 6:30 am EST / 11:30 am GMT / 7:30 pm HKT on February 28, 2024 [1]. - A conference call and audio webcast presentation with Q&A will follow the results announcement, scheduled for 7:30 am EST / 12:30 pm GMT / 8:30 pm HKT on the same day [2]. Group 2: Company Overview - HUTCHMED is an innovative, commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies and immunotherapies for cancer and immunological diseases [3]. - The company employs approximately 5,000 personnel, with a core team of about 1,800 dedicated to oncology and immunology [3]. - HUTCHMED has successfully brought three cancer drug candidates to market in China, with the first also marketed in the U.S. [3].

— First medicine approved under new "1+" mechanism by HKSAR Government, providing an important treatment option to patients in Hong Kong — — ELUNATE® is the first oral targeted therapy approved in Hong Kong for metastatic colorectal cancer regardless of biomarker status or prior types of therapies in almost a decade — — Fruquintinib already approved in mainland China, Macau SAR and the United States — HONG KONG, SHANGHAI, China and FLORHAM PARK, N.J., Jan. 29, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limit ...

— NDA accepted and granted Priority Review following its Breakthrough Therapy designation granted in January 2022 — — NDA is supported by data from successful Phase III ESLIM-01 trial in patients with adult primary immune thrombocytopenia who have received at least one previous therapy — HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Jan. 10, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:​HCM; HKEX:​13) today announces that the New Drug Application ("NDA") for sovleplenib for th ...

Financial Performance - HUTCHMED reported a strong performance in the first half of 2023, with a focus on prioritizing pipeline products and seeking partnerships for global reach[5]. - Total revenue for the first half of 2023 increased by 164% to $532.9 million, compared to $202 million in the same period of 2022[8]. - The company confirmed $258.7 million of the $400 million upfront payment from Takeda, with total recognized revenue of $258.7 million as of June 2023[8]. - The company anticipates total recognized revenue from Takeda to reach approximately $280 million by the end of the year[8]. - The net income attributable to the company for the six months ended June 30, 2023, was $168.6 million, compared to a net loss of $162.9 million for the same period in 2022[21]. - The company reported a significant increase in revenue from its oncology/immunology business, reaching $359.2 million, up 294% from $91.1 million in the previous year[73]. - The net cash flow from operating activities, excluding financing activities, was $219.3 million for the first half of 2023, compared to a negative $110.9 million for the same period in 2022[20]. - The company reported a total comprehensive income of $163,223 thousand, compared to a comprehensive loss of $167,047 thousand in 2022[139]. Product Development and Pipeline - The company completed a licensing agreement with Takeda Pharmaceuticals for furmonertinib, with an FDA priority review PDUFA date set for November 30, 2023, indicating significant potential for improvement over existing therapies[5]. - HUTCHMED has over 15 registration/registration intention studies ongoing for seven candidate drugs, showcasing its robust R&D capabilities[6]. - The company is preparing for the successful launch of more products and lifecycle extensions, with key data announcements expected later this year for sugemalimab and andecaliximab[6]. - In July 2023, the combination therapy of Fuzulonib and Sintilimab for advanced endometrial cancer completed patient recruitment in a Phase II study in China, supporting potential new drug registration[10]. - The company plans to complete patient recruitment for the Phase II/III study of the combination therapy with Sintilimab for renal clear cell carcinoma by the end of 2023[11]. - The company is conducting a Phase II study of the combination therapy with Tazemetostat in China, which has been initiated in February 2023[11]. - The company has initiated a Phase II/III study for furmonertinib combined with sintilimab for second-line treatment of locally advanced or metastatic renal cell carcinoma, aiming to recruit about 260 patients[38]. Sales and Market Performance - The company achieved strong sales growth for its self-developed oncology products in China, with all three marketed products now included in the National Reimbursement Drug List[6]. - Market sales of ELUNATE® (fruquintinib) increased by 12% to $56.3 million, maintaining a leading market share[8]. - Market sales of SULANDA® (surufatinib) surged by 66% to $22.6 million, reflecting the accumulation of treated patients over the past 18 months[8]. - Total product sales for the first half of 2023 increased by 16% to $101.3 million, compared to $87.4 million in the same period of 2022[9]. - The comprehensive revenue from other businesses increased by 57% to $173.7 million, compared to $110.9 million in the first half of 2022[16]. Research and Development - Research and development expenses decreased by 20% to $144.6 million for the first half of 2023, down from $181.7 million in the same period in 2022[21]. - The company is committed to sustainable development and has made satisfactory progress on 11 short- to long-term sustainability goals and indicators[19]. - The company plans to enhance climate risk-related actions and disclosures in the second half of 2023, following the recommendations of the TCFD[19]. - The company has six investigational candidates for hematological malignancies currently in clinical studies, including HMPL-523, HMPL-689, and HMPL-760[44]. Financial Position and Cash Flow - HUTCHMED has $856 million in cash resources as of the beginning of the second half of 2023, including $400 million received from Takeda Pharmaceuticals[6]. - The total cash and cash equivalents, along with short-term investments, amounted to $856.2 million as of June 30, 2023, up from $630.996 million on December 31, 2022[22]. - The company’s cash flow from financing activities was positive at $5.8 million for the first half of 2023, contrasting with a cash outflow of $74.6 million in the same period of 2022[75]. - The company has sufficient cash, cash equivalents, short-term investments, and unused bank loan facilities to meet its funding needs for at least the next twelve months[143]. Corporate Governance and Shareholding - The major shareholder, CK Hutchison Global Investments Limited, holds 332,574,650 shares, representing approximately 38.40% of the total shares[108]. - The company’s stock ownership structure indicates significant control by major shareholders, particularly CK Hutchison and its affiliates[108]. - The company is committed to maintaining high corporate governance standards to enhance shareholder value and protect stakeholder interests[133]. Clinical Trials and Regulatory Approvals - The company has initiated three Phase III studies for Savolitinib® in patients with MET amplification or overexpression after disease progression on Tarceva®[29]. - The SAVANNAH global Phase II study is expected to complete patient recruitment in the second half of 2023[29]. - The company has received orphan drug designation for furmonertinib for treating pancreatic neuroendocrine tumors, with positive results from two Phase III studies in China[40]. - The company plans to submit a marketing application to the National Medical Products Administration in 2024 for the combination therapy for advanced endometrial cancer, following the completion of patient recruitment in July 2023[37].

HUTCHMED (China) Limited (NASDAQ:HCM) Q2 2023 Earnings Conference Call July 31, 2023 8:00 AM ET Company Participants Mark Lee - SVP, Corporate Finance & Development Wei-Guo Su - CEO, Chief Scientific Officer & Executive Director Johnny Cheng - CFO & Executive Director Chen Hong - SVP & Chief Commercial Officer, China Mike Shi - EVP, Head, R&D and Chief Medical Officer Karen Atkin - EVP & COO Conference Call Participants Alec Stranahan - Bank of America Merrill Lynch Paul Choi - Goldman Sachs Group Mike Mitc ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示， 概不對因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 HUTCHMED (China) Limited 和黃醫藥（中國）有限公司 （於開曼群島註冊成立的有限公司） （股份代號：13） 和黃醫藥公佈 2023 年中期業績及最新業務進展 戰略方向得以有力執行，在規劃增長道路的同時實現近期價值，以武田製藥的全球合作為例證 收入增長164%（按固定匯率計算為173%）至5.33億美元，和黃醫藥的淨收益為1.69億美元 （其中包括武田製藥支付的首付款中已確認的2.59 億美元） 公司將於今天中國香港時間晚上8時正/ 英國夏令時間下午1時正/ 美國東部夏令時間上午8時正 舉行中期業績電話會議及網絡直播 公司將於今年第四季度舉辦資本市場日（Capital Markets Day） 和黃醫藥（中國）有限公司（簡稱「和黃醫藥」、「本公司」或「我們」）是一家處於商業化階段的創新型生物醫 藥公司，今日公佈截至 2023 年 6 月 30 日止六個月的未經審核財務業績以及提供關鍵臨 ...